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Abstract
Background: There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens
their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C,
a life expectancy of less than 12 months and no other treatment options.
Methods: A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as
part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom.
Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks
post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of
sustained virologic response for patients receiving daclatasvir and sofosbuvir with or without ribavirin using
hierarchical Bayesian modelling.
Results: The 249 patients included had a median age of 56 years; most were male (78%), hepatitis C genotype
1 (75%), treatment experienced (65%) and with decompensated cirrhosis (59%). Many had had a liver transplant
before receiving daclatasvir (40%). Of the 249 patients, 242 patients received daclatasvir and sofosbuvir and either reached
12 weeks post treatment or died during (n = 9) or after treatment (n = 4) or were lost to follow up during
treatment (n = 1). The estimated rate of sustained virologic response at 12 weeks post treatment was 87%
(95% credible interval 75 to 94%) for previously treated genotype 1 patients with decompensated cirrhosis.
Conclusions: Daclatasvir with sofosbuvir is an effective treatment in clinical practice for hepatitis C genotype 1 patients
with decompensated cirrhosis.
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Background
Chronic hepatitis C often leads to cirrhosis and hepato-
cellular carcinoma [1]. While the prevalence of hepatitis
C virus (HCV) infection is expected to decline world-
wide, the number of individuals with end stage liver disease
is projected to rise [2] and with it, the cost of healthcare for
these individuals [3]. Earlier standard treatment with
subcutaneous pegylated interferon alfa and oral ribavirin
achieved sustained virologic response (SVR) rates of only
50% or less in patients infected with HCV genotype 1 [4],
although SVR rates were as high as 60 to 80% in geno-
types 2, 3 and 6 [4, 5]. In addition, this treatment caused
potentially serious side effects and was therefore contrain-
dicated in patients with decompensated cirrhosis [4].
Daclatasvir, a HCV NS5A replication complex inhibitor,
has shown encouraging results in clinical trials across mul-
tiple genotypes, both in interferon-based regimens and in
all oral regimens without interferon [6, 7]. The combination
of daclatasvir and sofosbuvir, a nucleotide analogue HCV
NS5B polymerase inhibitor, has shown high rates of SVR in
patients with HCV genotype 1 [8, 9]. However there is
limited evidence for the effectiveness of this treatment
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combination in patients whose advanced cirrhosis threatens
their life expectancy [10–12]. There is also uncertainty
about the optimal duration of treatment and whether
ribavirin should be added to the combination [10–12].
A Named Patient Programme (NPP) for daclatasvir in
Europe included patients from 2012 to 2015 with advanced
chronic HCV, a life expectancy of less than 12 months and
no other treatment options. Here we summarise the char-
acteristics of the patients in this programme and estimate
their rate of SVR when given daclatasvir in combination
with sofosbuvir.
Methods
Patients
The first use of daclatasvir in Europe outside clinical trials
was via Bristol-Myers Squibb’s (BMS) early access pro-
grammes. The NPP was one of these programmes. Patients
were eligible to participate in the NPP if according to their
physician: (1) the patient was an adult with chronic
hepatitis C (regardless of genotype) at high risk of de-
compensation or death within 12 months; and (2) there
were no satisfactory alternative treatments options for
the patient and available treatment options had been
exhausted; and (3) the patient was ineligible to partici-
pate in a clinical trial where his or her infection might
be treated satisfactorily or there was no ongoing clinical
trial in the patient’s country of residence.
Collaborative agreements were later signed between
BMS and HCV registries or healthcare institutions with
HCV databases in six European countries. These agree-
ments allowed the transfer of individual patient data for
patients in a NPP to a third party, the Basel Institute for
Clinical Epidemiology and Biostatistics, for analysis. BMS
did not have any access to individual patient data. The insti-
tutions providing data were: the Department of Internal
Medicine III, at the Medical University of Vienna (Austria);
eight hospitals in the Danish Database for Hepatitis B and
C (Denmark); the Hepa C registry (Spain); the Karolinska
Institutet, at Karolinska University Hospital Huddinge
(Sweden); the University Hospital Geneva (Switzerland);
and seven hospitals in the HCV Research UK registry
(United Kingdom). All HCV registries or databases used
in this study contained data prospectively collected
from adult patients who had given informed consent.
We planned to also include data from Italy but agree-
ments with suitable institutions have yet to be signed.
To be eligible for this retrospective cohort study,
patients had to start any daclatasvir containing regimen
under a NPP (and not under any other early access
programme) and have data in one of the above HCV
databases. Patients were recruited from December 2012
until August 2014 when daclatasvir was approved for
use in Europe but the exact dates varied between countries
because in some countries, the NPP was replaced by
another early access program.
Statistical methods
The primary objective of this study was to estimate the
effectiveness of daclatasvir in combination with either
sofosbuvir or simeprevir as measured by the rate of sus-
tained virologic response at 12 weeks after the end of
treatment (SVR12). However only a single patient re-
ceived daclatasvir with simeprevir, so our analyses were
restricted to patients receiving daclatasvir and sofosbuvir,
with or without ribavirin. SVR12 was defined as HCV
RNA either undetectable or below the assay's lower limit
of quantification.
Secondary objectives were to summarise the demo-
graphic and clinical characteristics of patients receiving
daclatasvir and to assess effectiveness using other mea-
sures. Other measures of effectiveness available from all
registries included the virologic response at the end of
treatment and the sustained virologic response at four
weeks after the end of treatment (SVR4).
The protocol (ClinicalTrials.gov NCT02531269) specified
an intent-to-treat analysis such that failure to achieve a
SVR was assumed if a patient died or was lost to follow up,
or if a response was missing and sufficient time had elapsed
since the patient finished treatment for that response to be
measureable. There was an appreciable rate of mortality in
these patients. As a consequence, a decision was made
prior to any modelling to add an as-treated analysis in
which patients with no recorded response were excluded
(either because of death, loss to follow up or a missing
response). In both intent-to-treat and as-treated ana-
lyses, a SVR at four or 12 weeks was assumed where a
response was missing but the patient had a SVR at a
later date.
SVR rates were estimated using hierarchical Bayesian
modelling because small samples were anticipated from
most databases. Each SVR rate was estimated under four
models of increasing complexity. In all models we
assumed responses were binomially distributed with a
different rate for each database and that rates for each
database were normally distributed. The first model
was without covariates and with an uninformative
prior for between database variability; the second model in-
cluded covariates—for genotype, prior treatment and cir-
rhosis when starting the current treatment—so that data
from each database could be considered exchangeable [13].
The third and fourth models were a repeat of the first two
but with a weakly informative prior for between database
variability. Models with covariates provide estimates of the
SVR rate in a group of reference patients (here HCV
genotype 1 patients, previously treated but now with
decompensated cirrhosis); the model can then be used
to estimate SVR rates in other covariate subgroups
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(such as previously treated genotype 1 patients with
stable or no cirrhosis).
With a small number of databases, our uninformative
prior for between database variability—a uniform distri-
bution on the standard deviation of the between data-
base variability—could lead to ‘under-pooling’ of data
[13]. Therefore, in the last two models, we used a
weakly informative half-Cauchy prior with its scale par-
ameter set at the prior standard deviation [13] assum-
ing that the lowest and highest SVR rates between
databases would be covered with 95% probability by a
range of odds ratios from 1/4 to 4 relative to the aver-
age across all databases.
Adding covariates essentially accounts for what could
be material differences in patient mix between databases.
Weakly informative priors were used for this adjustment:
distributions where ‘the percentiles of the prior distribu-
tion would be viewed as at least reasonable if not liber-
ally inclusive by all those working in the research topic’
[14]. Weakly informative priors restrict covariate effects
to a range of values that is clinically sensible, ruling out
extreme values that no knowledgeable clinician would
find plausible [15]. The effects of genotype 3 and of
genotypes other than 1 or 3 were both assumed to be
of ‘uncertain direction’ (prior odds ratio (OR) 1.0, 95%
credible interval (CI) 0.25 to 4.0); no prior treatment
was assumed to be ‘possibly beneficial’ (prior OR 1.5,
95% CI 0.38 to 6.0); and no or stable cirrhosis was
assumed to be ‘probably beneficial’ (prior OR 2.0, 95%
CI 0.5 to 8.0) [16, 17]. There is clinical interest in the
value of including ribavirin in treatment combinations
but limited information [18, 19]. Given adequate data
were collected on the use of daclatasvir and sofosbuvir
both with and without ribavirin, the fourth model was
extended to include an additional covariate for ribavirin
use, with its effect assumed to be of ‘uncertain direction’
(prior OR 1.0, 95% CI 0.25 to 4.0).
We report estimated SVR rates and their 95% CI from
each model. Fitting a sequence of models allowed us to
check that as models became more complex, estimates
varied between models in a logical fashion. However the
most complex fourth model seems the most appropriate
because it better meets the assumption of exchangeability
between databases and gives rise to greater pooling of data
across databases. Exchangeability implies that each database
is independent of the others and, after adjusting for covari-
ates, contains identically distributed data [13]. Models were
fit using R 3.1.0, R2WinBUGS 2.1–20 and WinBUGS 1.4.3.
Results
Patients
Of the 249 NPP patients identified in the six databases, 246
patients started daclatasvir and sofosbuvir (Fig. 1) with or
without ribavirin (65 and 181 patients respectively). At the
time of analysis, four of the 246 patients had not been
followed for at least 12 weeks after the end of treat-
ment, so that the SVR12 intent-to-treat analysis was of
242 patients. Of these 242 patients, 13 died prior to
12 weeks after treatment, one was lost to follow up during
treatment and a response was missing for three patients so
that the SVR12 as-treated analysis was of 225 patients. Of
the 14 patients that died or were lost to follow up prior to
12 weeks after treatment, 13 had decompensated cirrhosis.
The remaining patient received a second liver transplant
during treatment and died before completing treatment.
Most of the 249 NPP patients were male (78%), with a
median age of 56 years (Table 1). Most had HCV genotype
1 (75%), were treatment experienced (65%), had advanced
fibrosis or cirrhosis (82% F3-F4) and decompensated cir-
rhosis (59%) and many had had a liver transplant (40%).
Those given ribavirin were less likely to have decompen-
sated cirrhosis (55%) and more likely to have had a liver
transplant (44%) than those not given ribavirin (61% and
38% respectively). Liver transplantation during treatment
was reported for 27 patients (11%); 21 of these patients
had decompensated cirrhosis.
For the 246 patients starting daclatasvir and sofosbuvir
with or without ribavirin, the planned treatment duration
was 24 weeks for all but three patients—these three
patients were to receive 8, 12, and 20 weeks of treat-
ment. Among the 243 patients that were to receive
24 weeks of treatment, the actual treatment duration
was known for 218 patients: 187 (86%) were treated
for between 23 and 25 weeks, 16 (7%) were treated for
fewer than 23 weeks and 15 (7%) were treated for more
than 25 weeks. Where known, the median duration of
treatment was the same for those treated with and without
ribavirin: 168 days (interquartile range 168 to 168) for
those treated with ribavirin and 168 days (interquartile
range 167 to 169) for those treated without ribavirin.
Observed effectiveness
Of the 234 patients that completed treatment, an end of
treatment response was missing for 15 patients; otherwise
all patients had an end of treatment virologic response. 92%
of intent-to-treat patients and 97% of as-treated patients
had a SVR4; 90% of intent-to-treat patients and 97% of
as-treated zpatients had a SVR12 (Table 2). Rates of
SVR4 and SVR12 varied between countries, from 82 to
100%: this variability in response rates between countries
was expected because in all countries except Spain, re-
sponse rates were estimated from fewer than 30 patients.
Of the six patients that failed to achieve a SVR12, all
had decompensated cirrhosis, five were treatment expe-
rienced and none received ribavirin (Table 3). For one
patient, the duration of treatment was not known and
the end of treatment response was missing; the other
five all received at least 20 weeks of treatment and had
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an end of treatment virologic response. Four of the five
then had detectable viremia within 4 weeks after the end
of treatment; the remaining patient had detectable
viremia between 4 and 12 weeks after the end of treat-
ment. Of the four patients with detectable viremia within
4 weeks: one was found to have Y93H resistance-associated
variant (RAV) HCV; one had both Y93H and Q30H RAV
HCV; the virus could not be sequenced for one patient but the
patient was successfully re-treated with ledipasvir, sofosbuvir
and ribavirin; the fourth patient was found to have L31M,
L31I and Y93HRAVHCV but was also successfully re-treated
with ledipasvir, sofosbuvir and ribavirin. The remaining pa-
tient with detectable viremia between 4 and 12 weeks was
genotype 3a andwas found to haveY93HRAVHCV.
Estimated effectiveness
Estimates from the fourth hierarchical Bayesian model
are shown for patients with HCV genotype 1, previously
treated and now with decompensated cirrhosis (Table 4).
These patients were selected as the reference group
because they were typical of those treated in the NPP.
For such patients, the estimated rate of SVR4 was 89%
(95% CI 76 to 96%) and 96% (95% CI 86 to 100%) in
intent-to-treat and as-treated analyses respectively; the
estimated rate of SVR12 was 87% (95% CI 75 to 94%)
and 97% (95% CI 89 to 100%) in intent-to-treat and as-
treated analyses respectively. Estimates from all four
models are shown in Additional file 1: Tables S1 to S4.
The model provides estimates of the association between
virologic response and covariates in the form of posterior
OR relative to the response in reference patients. In the
SVR12 intent-to-treat analysis, these estimates were: geno-
type 3, OR 0.69 (95% CI 0.25 to 1.54); other genotypes OR
1.06 (95% CI 0.32 to 2.77); no or stable cirrhosis, OR 6.73
(95% CI 2.42 to 16.1); no prior treatment, OR 0.92 (95% CI
0.39 to 1.89). Extending this model so that it includes an
Fig. 1 Patient flow. Patients included in intent-to-treat and as-treated analyses of sustained virologic response at four weeks after the end of treatment
(SVR4) and at 12 weeks after the end of treatment (SVR12)
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additional covariate for ribavirin use gives a posterior OR
for this covariate of 2.36 (95% CI 0.86 to 5.42).
The model can then be used to estimate effectiveness
in other covariate subgroups rather than in reference
patients. Our results suggest a higher rate of SVR in NPP
patients without decompensated cirrhosis. For patients
with HCV genotype 1, previously treated but with stable
or no cirrhosis, the estimated rate of SVR12 was 97%
(95% CI 93 to 99%) and 99% (95% CI 96 to 100%) in
intent-to-treat and as-treated analyses respectively. Our
results also suggest that treatment might be more effective
in NPP patients if it includes ribavirin. For patients with
HCV genotype 1, previously treated and now with decom-
pensated cirrhosis, the estimated rate of SVR12 in an
intent-to-treat analysis was 92% (95% CI 81 to 98%)
and 85% (95% CI 73 to 93%) with and without ribavirin
respectively.
Discussion
This study shows that 24 weeks of daclatasvir and
sofosbuvir is an effective treatment for HCV in patients
with advanced liver disease, with estimated rates of SVR12
of 87% (95% CI 75 to 94%) and 97% (95% CI 89 to 100%)
in intent-to-treat and as-treated analyses respectively. The
data are consistent with our expectation that it is easier to
treat patients with no or stable cirrhosis because our
posterior OR (6.73, 95% CI 2.42 to 16.1) suggests that
treatment at an early stage of infection is even more
Table 1 Patient characteristics when starting hepatitis C (HCV) treatment with daclatasvir (n = 249)
Characteristics All Genotype Ribavirin
1a 3b Otherc With Without
n = 249 n = 187 n = 40 n = 22 n = 66 n = 183
Age, median (years) 56 56 55 55 55 57
Male (%) 78 75 85 91 85 76
HIV co-infection (%) 10 8 15 14 11 9
Prior HCV treatment (%) 65 69 48 64 65 65
Cirrhosis (%)
- No 14 16 5 14 18 13
- Compensated 27 21 48 36 27 26
- Decompensated 59 63 48 50 55 61
Child Pugh class (%)
- A 27 27 20 41 29 26
- B 33 37 23 14 33 32
- C 8 9 3 9 5 9
- Unknown 33 27 55 36 33 32
Fibrosis stage (%)
- < F3 9 9 5 14 9 9
- F3 – F4 82 83 73 82 82 81
- Unknown 10 8 23 5 9 10
Hepatocellular carcinoma (%)
- Never 58 56 65 68 61 57
- Past 17 19 13 14 18 17
- Current 12 13 10 9 15 12
- Unknown 12 12 13 9 6 14
Liver transplantation (%)
- Never 34 31 50 32 27 36
- On list 13 14 13 9 11 14
- Before current treatment 40 40 33 50 44 38
- During current treatment 11 13 3 9 12 10
- Unknown 2 3 3 0 6 1
aGenotypes 1 (n = 14), 1a (n = 58), 1a/b (n = 3), and 1b (n = 112)
bGenotypes 3 (n = 18), 3a (n = 21) and 3 h (n = 1)
cGenotypes 2 (n = 4), 4 (n = 17) and 5 (n = 1)
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beneficial than we anticipated (prior OR 2.0, 95% CI 0.5
to 8.0). The data do not support our expectation that it
is easier to treat naive patients, because our posterior
OR (0.92, 95% CI 0.39 to 1.89) suggests that treatment
naivety is less beneficial than we anticipated (prior OR
1.5, 95% CI 0.38 to 6.0). Unfortunately there is little
information in these data on how the rate of SVR varies
with genotype: posterior ORs for genotype 3 and for
other genotypes relative to genotype 1 (OR 0.69, 95%
CI 0.25 to 1.54, and OR 1.06, 95% CI 0.32 to 2.77, re-
spectively) are not materially different from our prior
ORs (both 1.0, 95% CI 0.25 to 4.0). However since the
intervals of these posterior ORs are contained within
the interval of the prior OR, the data are consistent
with our expectation that the rate of SVR does not vary
markedly with genotype although the posterior OR for
genotype 3 suggests this genotype could be harder to
treat. Had we used an alternative prior for genotype 3
reflecting an expectation that genotype 3 would be
harder to treat (prior OR 0.67, 95% CI 0.17 to 2.7), we
would have found weak support in the data for this
position (posterior OR 0.52, 95% CI 0.20 to 1.14)
In an additional analysis, we extended our model to
include a covariate for ribavirin use. The shift in OR for this
covariate (prior OR 1.0, 95% CI 0.25 to 4.0; posterior OR
2.36, 95% CI 0.86 to 5.42), suggests ribavirin use might be
beneficial in these patients. Patients that received ribavirin
do not seem materially different from those that did not
(Table 1) and both groups were treated for a similar dur-
ation. The estimated rate of SVR12 in an intent-to-treat
analysis was 92% (95% CI 81 to 98%) and 85% (95% CI 73
to 93%) with and without ribavirin respectively. Other stud-
ies suggest that adding ribavirin to this combination is
beneficial in patients with decompensated cirrhosis [20, 21]
but unnecessary when treating patients without cirrhosis
[8]; a pattern seen in other oral interferon-free treatment
combinations [19].
The strengths of this study include data collected in
clinical practice and from patients with advanced liver
Table 3 Observed sustained virological response rates in
subgroups at 12 weeks (SVR12) after completing therapy with
daclatasvir and sofosbuvir, with or without ribavirin
Subgroups SVR12
As-treated Intent-to-treat
% Fraction % Fraction
Genotypea 1 98 171/174 92 171/186
3 94 33/35 85 33/39
Other 94 15/16 88 15/17
Cirrhosis None or compensated 100 93/93 99 93/94
Decompensated 95 126/132 85 126/148
Prior treatment Naive 99 75/76 88 75/85
Experienced 99 144/149 92 144/157
Ribavirin Without 96 157/163 88 157/178
With 100 62/62 97 62/64
Overall 97 219/225 90 219/242
aGenotype for the 6 patients without a sustained virologic response 12 weeks
after the end of treatment: 1a, 1b (n = 2), 3a (n = 2) and 5a
Table 4 Estimates from a hierarchical Bayesian model of the
sustained virological response rates at 4 weeks (SVR4) and at
12 weeks (SVR12) after completing therapy with daclatasvir and
sofosbuvir, with or without ribavirin
Estimate SVR4 SVR12
As-treated Intent-to-treat As-treated Intent-to-treat
Country % 95% CI % 95% CI % 95% CI % 95% CI
Austria 97 87–100 92 81–99 98 89–100 88 75–96
Denmark 93 77–100 88 73–97 98 89–100 87 73–95
Spain 98 95–100 92 95–100 98 94–100 89 83–94
Sweden 96 79–100 90 73–100 97 85–100 87 72–96
Switzerland 82 56–97 82 59–94 82 57–97 84 64–93
UK 96 80–100 82 52–95 97 83–100 82 56–93
Overall 96 86–100 89 76–96 97 89–100 87 75–94
These estimates apply to patients with genotype 1 hepatitis C, previously
treated and now with decompensated cirrhosis
Table 2 Observed sustained virological response rates at 4 weeks (SVR4) and at 12 weeks (SVR12) after completing therapy with
daclatasvir and sofosbuvir, with or without ribavirin
Observed SVR4 SVR12
As-treated Intent-to-treat As-treated Intent-to-treat
Country % Fraction % Fraction % Fraction % Fraction
Austria 100 14/14 100 14/14 100 13/13 93 13/14
Denmark 94 17/18 89 17/19 100 17/17 89 17/19
Spain 99 141/142 94 141/150 99 138/140 92 138/150
Sweden 100 15/15 94 15/16 100 15/15 94 15/16
Switzerland 85 23/27 82 23/28 85 22/26 85 22/26
UK 100 14/14 82 14/17 100 14/14 82 14/17
Overall 97 224/230 92 224/244 97 219/225 90 219/242
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disease including many patients with decompensated
cirrhosis (59%) that previously were difficult to treat.
Our data come from a number of European countries
and estimates have been appropriately averaged over
different health care systems. The limitations include a
higher level of missing supporting data than would be
expected in a controlled trial. Most patients in this
study were infected with HCV genotype 1, so that we
cannot reliably estimate the effectiveness of this treatment
combination in other genotypes or draw conclusions about
whether effectiveness differs between genotypes. And most
countries contributed only a small number of patients, so
that we needed to use advanced statistical methods to
sensibly combine data but then more effort is required
to interpret our results.
The results of this study are consistent with results from
recently completed Phase 2 and 3 studies and with recently
published or preliminary results from other early access
programmes. In recent Phase 2 and 3 studies, the treatment
combination of daclatasvir and sofosbuvir achieved a rate of
SVR12 above 95% in genotype 1 patients without cirrhosis
[8]; rates above 95% in both naive and previously treated
genotype 1 patients co-infected with HIV when treated for
12 weeks [22], and a rate above 95% in genotype 3 patients
without cirrhosis [23]. A number of Phase 3 studies of
daclatasvir and sofosbuvir (with or without ribavirin)
have included at least some patients with cirrhosis and
results suggest that lower rates of SVR12 are to be
expected: 63% of 32 genotype 3 patients with compen-
sated cirrhosis achieved a SVR12 after 12 weeks of
treatment (without ribavirin) [23]; 86% of 36 genotype
3 patients with compensated cirrhosis achieved a SVR12
after 12 or 16 weeks of treatment (with ribavirin) [21]; and
79% of 34 genotype 1 patients with decompensated
cirrhosis (Child-Pugh class B or C) achieved a SVR12
after 12 weeks of treatment (with ribavirin) [24]. Data
from other early access programmes suggest that this
treatment combination is just as effective after liver
transplantation [25, 26] but effectiveness is reduced in
patients with HCV genotype 3 or decompensated
cirrhosis [20, 26, 27].
Conclusions
Patients with decompensated cirrhosis have always been
difficult to treat [1, 28]. With direct acting antivirals,
efficacy is reduced in such patients and it is not yet clear
which treatments are best [28–30]. For the moment, the
recommended treatment is sofosbuvir in combination
with either daclatasvir, ledipasvir or velpatasvir [11, 12]
but such recommendations are frequently updated. This
study provides evidence that the combination of daclatasvir
and sofosbuvir is an effective treatment in clinical practice
for HCV genotype 1 patients with decompensated cirrhosis.
The study adds to limited evidence that, for these patients,
treatment is more effective if ribavirin is added to the
combination [20, 21]. Other questions remain: whether
fewer than 24 weeks of treatment erodes effectiveness
in these patients – and by how much [20, 21, 23, 24, 27];
whether this treatment is as effective in HCV genotype 3
patients with decompensated cirrhosis [20, 21, 23, 26]; and
whether the combination of daclatasvir and sofosbuvir is
more effective than other treatment combinations for
patients with decompensated cirrhosis [20].
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